Medical Device Marketing Regulations in the United States

The U.S. medical device market hit $188.68 billion in 2024, and Fortune Business Insights expects it to climb to $314.96 billion by 2032. That 6.8% compound annual growth rate draws investors and regulators to the same room for very different reasons. This piece covers the second group: how FDA's rules on classification, labeling, and claims decide what a device company can actually say about its product, and where marketing teams keep tripping over lines they didn't know were there.

A market this size doesn't just pull in competitors and capital; it pulls in scrutiny, line by line, claim by claim, and the Government Accountability Office has kept FDA's oversight of medical products on its High-Risk List since 2009. Fifteen-plus years on that list is not a fluke of bureaucratic inertia. It's a standing signal that this space gets watched differently than most consumer categories. Here's the position worth stating up front: treating device promotion as something legal signs off on after the creative team finishes is backwards, and it's the single most common way companies end up on the wrong end of a warning letter. Get the sequence right, or the cleverest copy in the world won't save the launch.

How the FDA's three-class device system determines which marketing pathway applies

Before 1976, FDA barely touched medical devices before they hit the market. Then Congress passed the Medical Device Amendments, folding devices into the Federal Food, Drug, and Cosmetic Act and building the three-tier risk system still running the show today. Class I covers low-risk devices that general controls alone can handle on their own. Class II is the middle tier, moderate risk, and it's where most devices actually live; it needs both general and special controls, and the main clearance route is the 510(k), covered next. Class III sits at the top: devices that support or sustain life, or carry a real chance of serious harm, and these need full Premarket Approval before a single ad can run.

Here's what marketing teams get wrong most often, and it takes working through a few cases to see the pattern: classification isn't a paperwork step handled once in a back office. It sets the outer boundary of every claim a company can make and every audience it can make that claim to. A device marketed before its required premarket review wraps up is legally misbranded, full stop, no matter how careful or accurate the promotional copy reads. Accuracy doesn't save anyone if the clearance itself never happened. Campaign planning has to start with confirmed classification, not a guess based on what a similar product down the hall did last quarter.

The premarket pathways that authorize a device for promotion

The 510(k) pathway handles most device clearances in the U.S., and it works by comparison rather than proof built from scratch. A manufacturer shows FDA that its new device is substantially equivalent to something already on the market, a predicate device, with the same intended use and the same or equivalent technological traits. Companies have to notify FDA at least 90 days ahead of intended marketing, and under the current Medical Device User Fee Act agreement, FDA has committed to deciding 95% of 510(k)s within 90 FDA review days. One distinction is worth sitting with: a 510(k) gets a device "clearance," a specific legal term FDA reserves for this pathway, distinct from "approval." The device is authorized to be sold for the specific intended use cleared. Nothing more expansive than that.

PMA is the heavier lift, reserved for Class III devices, running through a full scientific review under section 515 of the FD&C Act. What comes out the other side is narrow by design: the approved indication is the promotional ceiling, and claims have to track it precisely.

De Novo exists for devices that are genuinely new, low-to-moderate risk, with no predicate to compare against. A successful De Novo review doesn't just clear one device; it creates a brand-new classification, which then becomes the predicate other companies point to in their own 510(k) filings down the line.

Humanitarian Device Exemption applies to devices treating conditions affecting fewer than 8,000 people annually in the U.S., a genuinely small population. HDE devices skip the effectiveness requirements a PMA demands, so the evidence behind them is thinner, and the promotional claims allowed follow that thinner basis.

Investigational Device Exemption lets a company run clinical studies to build the data a future PMA or 510(k) will need. Worth repeating because it trips people up: an IDE device carries none of the authorizations needed for market, and any promotional activity during this window is off the table entirely, including a soft-launch teaser campaign or a "coming soon" landing page with a claims list attached.

One procedural wrinkle is easy to miss if nobody on the team reads FDA's operational notices closely: the eSTAR submission portal became mandatory for 510(k)s on October 1, 2023, and FDA extended that requirement to PMAs and De Novo submissions in October 2025. It changes how submission timelines get built, and teams planning launch dates around an assumed review window should account for that now, not discover it two weeks before a trade show.

What "labeling" actually covers and why it reaches further than most marketers expect

Ask a marketer what "labeling" means and the answer usually involves the sticker on the box. That answer is wrong, and it's wrong in a way that gets companies cited. FDA's definition, under 21 CFR Part 801, covers Instructions for Use, sales brochures, the company website, product pages, training materials, speaker slide decks used at conferences, and even the user interface on device software. Any written, printed, or graphic material that goes along with or supplements the device, in any medium, can count as labeling subject to FDA review. The sticker on the box is a small fraction of what qualifies, and most marketing teams have no idea how much of their output falls under this definition until someone tells them the hard way.

At the 510(k) stage, the submission has to include device classification, a device description, a comparison against the predicate, the intended use, and proposed labeling. That proposed labeling, the version submitted at clearance, becomes the ceiling for every promotional claim made afterward. Nothing downstream gets to say more than what got submitted.

This is also where enforcement tends to start. Labeling errors rank among the top five most common Form 483 citations FDA issues to device firms, ahead of many clinical and manufacturing findings. Sit with that ranking for a second: labeling outranking manufacturing defects as a citation category says the real risk concentrates somewhere most teams aren't instinctively looking. Marketing teams producing any piece of collateral about a device are, whether they think of it this way or not, producing regulated labeling. Build every asset as though an FDA reviewer will eventually sit down and read it, because one probably will.

The rules governing what claims can and cannot be made in device promotion

The baseline rule is simple to state and harder to apply consistently: devices must be promoted in line with cleared or approved labeling, and every claim needs to be accurate and not misleading. Layered on top is the fair balance requirement, which says risks can't be minimized through clever wording, misleading visuals, or convenient omission, and benefits can't get inflated past what the clinical evidence supports. This isn't unique to FDA labeling, either; FTC applies its own version of fair balance to advertising, so the same standard shows up twice, from two different directions, meaning one agency's sign-off never fully covers the other's.

The mechanical piece of this is Form FDA 2253. Manufacturers have to submit specimens of promotional labeling and advertising to FDA when a piece of material first goes into circulation, and this applies across the board for prescription devices. There's some flexibility for interactive or real-time digital content, quarterly submission instead of piece-by-piece, but the paperwork is not optional. FDA processes a large volume of these submissions every year, and that volume alone says the promotional review net is cast wide.

Substantiation matters just as much as disclosure. Health-related claims need backing from clinical trials or large-scale scientific studies, not an internal data set from a pilot program or a handful of glowing testimonials from early adopters. Everything also has to match across channels. If the sales brochure says one thing about a device's intended use and the website says something slightly broader, that gap isn't a rounding error; it's a compliance flag, and exactly the kind of inconsistency reviewers are trained to spot.

Off-label promotion: where the legal exposure is sharpest

Promote a device for something outside its cleared or approved indication, and the device becomes misbranded under the FD&C Act, a strict liability criminal statute. The statute is strict: the misbranding happened, the promotion happened, and intent provides no shelter. Nobody gets to argue they meant well. Consequences range from warning letters and enforcement actions to reputational fallout to, in the more serious cases, criminal misbranding charges.

There are narrow exceptions. A company can respond to an unsolicited request from a healthcare professional within defined limits, and it can hand out peer-reviewed scientific literature under specific conditions. Narrow is the operative word here; treating these exceptions like loopholes is how a company ends up explaining itself to FDA's Office of Chief Counsel.

A recurring pattern in this space involves wellness wearables and similar consumer products where marketing language pushes a product into medical device territory, drawing scrutiny a cleared diagnostic tool would face. The lesson extends past wearables specifically. Intended use isn't a line item filled out once during clearance and forgotten; marketing language shapes it after the fact, and marketing can walk a product straight into a regulatory category it was never built for.

There's a legal wrinkle worth flagging, even though it doesn't change anything today. Some legal observers think the Supreme Court's Loper Bright decision could eventually give courts more room to independently examine the statutory and regulatory framework FDA leans on to enforce off-label promotion rules. That's a situation to watch, not one where the rules have already changed. The intended use statement submitted at clearance remains the exact boundary of what's permissible to say, today and for the foreseeable future.

How FDA and FTC divide — and share — authority over device advertising

FDA and FTC operate under distinct but overlapping jurisdictions, and the boundaries matter for anyone running a campaign. FDA's jurisdiction covers labeling and promotional material that accompanies or supplements the device, regardless of medium. FTC's jurisdiction covers advertising claims in the broader media landscape, print, broadcast, digital, social, with a particular focus on consumer-facing promotion. Section 5 of the FTC Act bars unfair or deceptive acts or practices generally, and Section 12 gets more specific, targeting false advertisements for food, drugs, devices, and cosmetics by name. The underlying truth-in-advertising standard stays consistent across both: claims need to be truthful, not misleading, and backed up before they ever go out the door.

Between 2018 and 2022, FDA brought 255 enforcement actions related to medical device advertising, while FTC brought 67, according to agency officials cited in a GAO report. Work the ratio out and FDA's volume runs roughly four times FTC's, which tracks given how directly device labeling sits in FDA's lane. Still, 67 actions is a reminder that FTC exposure is real and separate, worth checking on its own rather than assumed to be covered by an FDA sign-off. Betting that FTC won't notice because FDA already looked is the wrong bet; the two agencies are not reading off the same checklist.

Here's the trap that keeps catching people: a single campaign can create liability with both agencies at once. A website overstating clinical benefit is FDA's problem because it's labeling, and it's FTC's problem because it's advertising to consumers. Compliance review that stops at FDA's labeling checklist and never runs FTC's substantiation standard against those same claims is only doing half the job. The other half doesn't go away just because nobody checked it.

Digital channels and social media under the same regulatory standards as traditional media

The internet runs under the same rulebook as everything else, and that's the part brands most often get wrong. Both FDA and FTC apply the same standards to social posts, digital ads, and website copy that they'd apply to a print ad or a television spot. A brand's Instagram caption, a paid search ad, an influencer's video, a product landing page: any of these can meet the legal definition of labeling, advertising, or occasionally both at once. FDA has been explicit that format limits, a 280-character cap, a 15-second clip, don't create an exemption. If the content discusses a regulated product, full compliance applies, no matter the platform. Brevity is not a legal defense, and treating a tweet as somehow lower-stakes than a print ad is exactly the assumption that gets companies cited.

Influencer marketing has drawn particular attention lately. On September 9, 2025, HHS and FDA jointly announced a crackdown on deceptive direct-to-consumer advertising that specifically named influencer promotion as a target. The action traced back to a presidential memorandum directing FDA, HHS, FTC, and the Department of Justice to sharpen oversight of DTC advertising, with special attention to how risk information gets presented, or doesn't, on digital platforms. HHS cited research finding that a substantial majority of direct-to-consumer therapeutic video ads qualified as misleading, a number big enough to drive an actual policy response instead of just a talking point.

The practical takeaway for brands running influencer partnerships: the same claims review applied to a formal ad campaign has to apply to that partnership, in full. A creator's independence from the company, the fact that they wrote their own script and picked their own angle, doesn't reduce the company's liability one bit. Real-time formats, live social video, webinars, carry the highest operational risk of all, simply because content gets made and published faster than most legal review cycles are built to keep up with.

Recent enforcement actions and the patterns they reveal for marketers

In 2025, FDA issued enforcement letters aimed at medical device marketing violations. The letters clustered around three recurring issues: manufacturers making claims outside their cleared intended use, devices with AI-based algorithms getting promoted without the authorization those specific features needed, and companies failing to apply Unique Device Identifiers or submit the required data to the Global Unique Device Identification Database.

The pattern described above is worth returning to here because it illustrates how marketing language can trigger a device reclassification on its own. Enforcement actions have involved companies FDA found marketing device products, without the required clearance. The products ended up deemed misbranded, and the failure traced back to one decision: bringing them to market before clearance was actually in hand.

Line those cases up against the 32 enforcement letters and three patterns come into focus, patterns that only surface once the individual cases get compared side by side rather than read in isolation. Intended-use drift is the first, where promotional claims quietly expand past the cleared indication over time, the kind of scope creep that happens one confident marketing meeting at a time. The second is AI and software features getting promoted before the regulatory authorization for those specific features exists, an increasingly common trap as devices add algorithmic capabilities faster than clearance paperwork can keep pace. The third is outright launching ahead of a completed premarket review, the Next Science pattern exactly. Zoom out further and the picture gets bigger still: FDA continued issuing enforcement letters across drugs, biologics, and devices, an agency actively enforcing its own rules at scale.

Building a compliant content operation for medical device marketing

None of the sections above are abstract regulatory trivia; they're the actual checklist a content operation needs to run against before anything gets published. Compliant device marketing starts with classification, which sets the outer edge of what can be claimed, and ends with a review process that treats every asset, brochure, tweet, or slide deck, as labeling subject to the same standard as the box insert.

A functional workflow puts legal and regulatory review upstream of creative production, because catching an off-label claim after the ad has already run only documents the problem instead of fixing it. Waiting for legal to review a finished campaign is like waiting until the plane has landed to check the flight plan: technically still useful, but not for the flight that already happened. A working system keeps one single source of truth for cleared intended use language that marketing, sales, and social teams all pull from, instead of each team working off its own read of what the product does. It runs FTC's substantiation standard against consumer-facing claims separately from FDA's labeling review, since satisfying one agency says nothing about the other. And it builds influencer and social content review into the same pipeline as traditional advertising, with enough lead time that a short-form video doesn't skip the process just because it's short.

The market keeps expanding, and the regulatory apparatus watching it isn't shrinking to match. Enforcement patterns point to recurring failure modes: intended-use drift and marketing that outruns clearance. Those three failure modes are documented, repeated, and avoidable, which is either reassuring or a little damning, depending on how a given company's last product launch actually went.